0.00
Cara Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
See More
Previous Close:
$15.96
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$22.12M
Revenue:
$20.97M
Net Income/Loss:
$-118.51M
P/E Ratio:
0.00
EPS:
-2.19
Net Cash Flow:
$-94.45M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Cara Therapeutics Inc Stock (CARA) Company Profile
Name
Cara Therapeutics Inc
Sector
Industry
Phone
203-406-3700
Address
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Compare CARA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CARA
Cara Therapeutics Inc
|
0.00 | 22.12M | 20.97M | -118.51M | -94.45M | -2.19 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
375.63 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
559.80 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
435.10 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
672.35 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
298.29 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-14-25 | Initiated | Raymond James | Outperform |
Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
Jun-12-25 | Initiated | Piper Sandler | Overweight |
May-21-25 | Initiated | Oppenheimer | Outperform |
May-15-25 | Initiated | BTIG Research | Buy |
Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jun-13-24 | Downgrade | Needham | Buy → Hold |
Jun-13-24 | Downgrade | Stifel | Buy → Hold |
Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
Nov-01-21 | Resumed | Canaccord Genuity | Buy |
Aug-03-21 | Initiated | JP Morgan | Neutral |
Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
May-29-19 | Reiterated | Laidlaw | Buy |
Feb-06-19 | Resumed | Jefferies | Buy |
Jan-15-19 | Initiated | BofA/Merrill | Neutral |
Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
Sep-13-18 | Initiated | Jefferies | Buy |
Aug-08-18 | Reiterated | Stifel | Buy |
Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
Mar-12-18 | Resumed | H.C. Wainwright | Buy |
Feb-12-18 | Upgrade | Janney | Neutral → Buy |
Jan-19-18 | Initiated | Seaport Global Securities | Buy |
Jun-30-17 | Downgrade | Janney | Buy → Neutral |
Jun-30-17 | Reiterated | Laidlaw | Buy |
Jun-30-17 | Reiterated | Stifel | Buy |
Mar-28-17 | Reiterated | H.C. Wainwright | Buy |
Mar-28-17 | Reiterated | Laidlaw | Buy |
Mar-10-17 | Reiterated | Laidlaw | Buy |
Oct-13-16 | Initiated | H.C. Wainwright | Buy |
Aug-08-16 | Reiterated | Needham | Buy |
View All
Cara Therapeutics Inc Stock (CARA) Latest News
Cara Therapeutics Inc to Host Earnings Call - ACCESS Newswire
This ‘Strong Buy’ Stock Could Be the Next Big Biotech Breakout - Yahoo Finance
This ‘Strong Buy’ Stock Could Be The Next Big Biotech Breakout - Barchart.com
Tvardi Therapeutics (NASDAQ:TVRD) Coverage Initiated at Raymond James Financial - Defense World
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - Business Wire
Tvardi Therapeutics director Shaheen Wirk resigns from board - Investing.com Australia
Tvardi Therapeutics director Shaheen Wirk resigns from board By Investing.com - Investing.com Nigeria
Raymond James Initiates Tvardi Therapeutics at Outperform - MarketScreener
Raymond James initiates coverage on Tvardi Therapeutics stock with Outperform rating - Investing.com Nigeria
Equities Analysts Offer Predictions for TVRD FY2025 Earnings - Defense World
Cantor Fitzgerald Initiates Coverage on Tvardi Therapeutics (NASDAQ:TVRD) - Defense World
Tvardi Therapeutics: A Catalyst-Driven Biotech Play with 130% Upside Potential - AInvest
Cantor Fitzgerald initiates coverage on Tvardi Therapeutics stock with Overweight rating - Investing.com
Cantor Fitzgerald Initiates Tvardi Therapeutics at Overweight With $52 Price Target - MarketScreener
Tvardi Therapeutics, Inc.(NasdaqCM: TVRD) added to Russell Microcap Growth Index - MarketScreener
Cara Therapeutics (NASDAQ:TVRD) Now Covered by Analysts at Piper Sandler - Defense World
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga
Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - MarketScreener
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com Canada
How To Trade (CARA) - news.stocktradersdaily.com
Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages - Defense World
Oppenheimer Begins Coverage on Cara Therapeutics (NASDAQ:TVRD) - MarketBeat
BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa
BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks
Cara Therapeutics (NASDAQ:TVRD) Raised to “Hold” at Wall Street Zen - Defense World
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World
BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com UK
Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN
Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire
Where are the Opportunities in (CARA) - news.stocktradersdaily.com
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire
Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Average Rating of “Hold” from Brokerages - Defense World
Cara Therapeutics Inc Stock (CARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):